Navigation Links
Race an important links to the risk of advanced colorectal cancer

For the first time an interesting report looks at the relationship between racial subgroups and colorectal cancer // outcome. This report is to appear in the August 1, 2005 issue of CANCER.

Colorectal cancer is a common cancer responsible for causing up to 11 percent of all cancer-related deaths in the United States . The Prognosis of the cancer is dependent on the stage of disease at the time of diagnosis.

The study reveals wide variations in colorectal cancer stage of diagnosis and mortality. Some ethnic groups have a 10 to 60 percent higher risk of stage III or IV colorectal cancer compared to some non-Hispanic whites. Some have 20 to 30 percent higher risk of death from the disease. The good news for Asian Americans and non-Hispanic whites is that they are less prone to have advanced disease compared to Native Americans and African Americans.

The researchers from the Fred Hutchinson Cancer Research Center in Seattle, reviewed patient data from the Surveillance, Epidemiology and End Results (SEER) program to look at the relationship between 18 racial categories and stage of disease and mortality. Analysis showed that African Americans, Native Americans, Asians/Pacific Islanders, and Hispanic whites were more likely to be diagnosed with advanced stages of colorectal cancer compared to non-Hispanic whites. They also found that African Americans, Native Americans, and Hispanic whites had higher risks of dying from colorectal cancer, while Asians/Pacific Islanders had a lower risk compared to non-Hispanic whites. More interestingly within the category of Asian/Pacific Islander, risk of stage IV disease and/or death was lower for Chinese, Japanese, and Indian/Pakistanis but elevated for Filipinos and Hawaiians compared to non-Hispanic whites. Within the category of Hispanic white, risk of stage IV disease and/or death compared to non-Hispanic whites was similar for Cubans and Puerto Ricans but increased for Mexicans and South/Ce
'"/>




Page: 1 2

Related medicine news :

1. Antidepressants-important role
2. Inherited gene important in ovarian cancer
3. Balanced diet important in cancer prevention
4. Evoprinter, a multigenomic comparative tool for rapid identification of functionally important DNA
5. Lifestyle plays an important role in determining one’s ag
6. Gene study links endometriosis, infertility
7. Study links Ritalin to Cancer
8. Study links diabetics to increased risk of urinary tract infections
9. Study links obesity to kidney failure
10. Gene Bias: Onomastics of Shared Surnames among Men Reveals Genetic links
11. Troubling Dry Eyes and Mouth links with Sj?gren’s Syndrom
Post Your Comments:
(Date:7/18/2008)...swire-USNewswire/ -- Two consumer,groups today fil... patent,on human embryonic stem cells held by the ...sumer Watchdog, formerly The Foundation for Taxpay...dation appealed to the U.S. Patent,Office,s Board ...rowed,WARF,s patent after the two groups requested...
(Date:7/18/2008)... within one hour before they undergo spinal surger...after the surgery, suggests a Johns Hopkins study ...Infectious Disease Journal (also available online...s outside of the golden one-hour window were three...ections at the surgery site, researchers report, p...
(Date:7/18/2008)...ptoms, but old drug offers new hope , , ... forward, one step back in the search for treatmen... studies in the July 19 issue of The Lancet , an ...lzheimer,s symptoms. But in a second report, a onc...ion of Alzheimer,s -- even though it cleared demen...
(Date:7/18/2008)...University of Pennsylvania School of Medicine have...ith familial Alzheimer,s disease disrupt the flow ...called PS1 and PS2 (presenilin 1 and 2), interact ... cell compartment. , "The ,calcium dysregulation...lzheimer,s disease has been suggested by previous ...
Breaking Medicine News(10 mins):Health News:Consumer Groups File Appeal on Challenge of Human Stem Cell Patent Held By WARF 2Health News:Averting postsurgical infections in kids: Give antibiotics within hour before first incision 2Health News:Alzheimer's Research Brings Progress, Setbacks 2Health News:Alzheimer's Research Brings Progress, Setbacks 3Health News:Alzheimer's Research Brings Progress, Setbacks 4Health News:Calcium may be the key to understanding Alzheimer's disease 2Health News:Calcium may be the key to understanding Alzheimer's disease 3
...ed by doctors and dentists according to a report r...rowa€?s Furness General Hospital is rated as good ...undly criticised the NHS services in Cumbria. The ... conducted by it is far more wide-ranging and toug...
...e neo-natal intensive care unit of the Rizal Medic...//effect was passed by the Philippine Health Secre...death of seven new born babies. The unfortunate d...rtified by the hospital to have occurred due to un...
...phenomenal rise in sexually transmitted diseases i...f the most common treatable sexually transmitted d...d to have increased four-fold in its incidence rat...ith new cases having been reported in both older a...
...erous, more so because its look and perception spe...lt’ status, and is becoming the life of many parti...that the hookah or the pipe is indeed a wolf in sh...redo, director of the Cancer Genetics and Epidemio...
Other Medicine News:Health News:Sexually Transmitted Diseases Soaring Due To Unsafe Sex 2
(Date:7/16/2008)... Raptor to Support Phase 2a Clinical Trial at UCSD...-- Raptor,Pharmaceuticals Corp. ("Raptor" or the "...ced the execution of a collaboration agreement (th...San Diego ("UCSD") to,include a Phase 2a clinical ... cysteamine bitartrate ("Cysteamine") in adolescen...
(Date:7/15/2008)... Fund Completion of Phase III Trials of Light Infu...tatic Colorectal Cancer and Phase I/II a... BELLEVUE, Wash., July 15 /- Light S...pany developing Light Infusion Therapy(TM),(Litx(T...nounced that it,has raised $40.1 million in a Seri...
(Date:7/15/2008)...Reports 92 Percent Response Rate to Combination Tr...ll/ -- Cephalon, Inc. (Nasdaq:,CEPH) announced tod...in the,Journal of Clinical Oncology, 92 percent of... cell non-Hodgkin,s lymphoma (NHL) responded to tr...e) for Injection plus rituximab.,This combination ...
(Date:7/14/2008)... VIEW, Calif., July 14 /- M...nounced it has initiated its,Phase 3 clinical prog...or,migraine., MAP0004 is orally inhaled and self-...oprietary Tempo(R) inhaler. In the company,s prior...ief in as fast as 10 minutes,with relief sustaine...
Breaking Medicine Technology:Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 2Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 3Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 4Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 5Light Sciences Oncology Raises $40.1 Million in Series C Financing 2Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 2Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 3Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 4Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 5MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 2MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 3MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 4Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 1Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 2Arobella Medical LLC Launches Qoustic Wound Therapy System 28TM 29 3174 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 1AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 2AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 4American Chemical Societys Weekly PressPac Feb 6 2008 11486 1American Chemical Societys Weekly PressPac Feb 6 2008 11486 2American Chemical Societys Weekly PressPac Feb 6 2008 11486 3American Chemical Societys Weekly PressPac Feb 6 2008 11486 4American Chemical Societys Weekly PressPac Feb 6 2008 11486 5American Chemical Societys Weekly PressPac Feb 6 2008 11486 6American Chemical Societys Weekly PressPac Feb 6 2008 11486 7American Chemical Societys Weekly PressPac Feb 6 2008 11486 8American Chemical Societys Weekly PressPac Feb 6 2008 11486 9FindCareHomes com Features New Interactive Tools and Free Services to Simplify the Search for Elder Home Care 11484 1FindCareHomes com Features New Interactive Tools and Free Services to Simplify the Search for Elder Home Care 11484 2
...ne 4, 2007 – Data presented,today at this ye...ASCO) meeting in Chicago show that a novel combina...uorouracil (5-FU) therapy UFT,(tegafur–uraci...ponse rate in the first-line treatment of metastat...(Study of CPT-11 with Oxaliplatin combined,with UF...
...ne 4, 2007 – Genta,Incorporated (Nasdaq: GNT...ase 2 clinical trial of its marketed product, Gani...b (Rituxan®;,Genentech/IDEC) and dexamethasone...in’s lymphoma (NHL). The data were,presented...Clinical,Oncology (ASCO) in Chicago, IL. , ,Previo...
Other Medicine Technology:Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 2Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 2Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 3Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 4Phase 2 Clinical Results of Ganite Plus Standard Therapy in,Patients with Relapsed/Refractory Lymphoma Presented at ASCO 5
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...
Medicine Products: